Literature DB >> 32578029

Reminiscence therapy-based care program relieves post-stroke cognitive impairment, anxiety, and depression in acute ischemic stroke patients: a randomized, controlled study.

Chunmei Cheng1, Wenjun Fan1, Chunhua Liu1, Yin Liu2, Xin Liu3.   

Abstract

BACKGROUND: Cognitive and mental impairments are common health problems in acute ischemic stroke (AIS) patients. In this study, we aimed to assess the benefit of a reminiscence therapy-based care (RTBC) program on cognitive impairment restoration, anxiety, and depression reduction in AIS patients.
METHODS: Totally 130 AIS patients were recruited in this randomized, controlled study and randomly assigned to the RTBC group or control group in 1:1 ratio for 12-month intervention. Mini-Mental State Examination (MMSE), Montreal cognitive assessment (MoCA), Hospital Anxiety and Depression Scale for anxiety/depression (HADS-A/HADS-D), and Zung self-rating anxiety/depression scale (SAS/SDS) were assessed at month 0 (M0), M3, M6, M9, and M12. Meanwhile, patients' satisfaction was also evaluated at M3, M6, M9, and M12.
RESULTS: RTBC increased MMSE score and MoCA score and reduced cognitive impairment patients' percentage assessed by MoCA score at M12 compared with control. RTBC reduced HADS-A score at M12, but not anxiety patients' percentage or severity by HADS-A at M12; besides, RTBC significantly lowered the SAS score at M9 and M12, and anxiety patients' percentage and severity by SAS at M12 compared with control. RTBC reduced HADS-D score at M9 and M12 (while statistically non-significant), but not depression patients' percentage or severity by HADS-D at M12; it decreased SDS score at M9 and M12, but not depression patients' percentage or severity by SDS at M12 compared with control. Additionally, RTBC obsessed higher patients' satisfaction at M3, M6, and M12 compared with control.
CONCLUSION: RTBC could help reduce cognitive impairment, anxiety, and depression in post-stroke management for AIS patients.

Entities:  

Keywords:  Acute ischemic stroke; Anxiety; Cognitive impairment; Depression; Reminiscence therapy

Mesh:

Year:  2020        PMID: 32578029     DOI: 10.1007/s11845-020-02273-9

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  1 in total

1.  The guided self-rating anxiety-depression scale for use in clinical psychopharmacology.

Authors:  G Gainotti; C Cianchetti; M Taramelli; C Tiacci
Journal:  Act Nerv Super (Praha)       Date:  1972
  1 in total
  5 in total

1.  Reminiscence therapy is a feasible care program for improving cognitive function, anxiety, and depression in recurrent acute ischemic stroke patients: a randomized, controlled study.

Authors:  Jiaying Yu; Yun Tang; Jingfeng Han; Jiawei Chen; Weiwei Lin; Wei Cui
Journal:  Ir J Med Sci       Date:  2022-07-27       Impact factor: 2.089

2.  Proposing a novel care program: reminiscence therapy involved care for anxiety, depression, and quality of life in postoperative cervical cancer patients.

Authors:  Xiaojing Liu; Kun Yuan; Xuekui Ye; Rui Liu
Journal:  Ir J Med Sci       Date:  2021-10-30       Impact factor: 2.089

3.  Reminiscence therapy exhibits alleviation of anxiety and improvement of life quality in postoperative gastric cancer patients: A randomized, controlled study.

Authors:  Lisha Zhang; Yanling Li; Wenjia Kou; Yue Xia; Xiaohui Yu; Xin Du
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

4.  Reminiscence Therapy as a Potential Method to Improve Psychological Health and Quality of Life in Elderly Hepatocellular Carcinoma Patients: A Randomized, Controlled Trial.

Authors:  Teng Li; Bin Li; Lu Tan; Bo Lv
Journal:  Front Surg       Date:  2022-08-02

5.  Reminiscence therapy-based care program serves as an optional nursing modality in alleviating anxiety and depression, improving quality of life in surgical prostate cancer patients.

Authors:  Ting Huang; Hongmei Su; Shi Zhang; Yawen Huang
Journal:  Int Urol Nephrol       Date:  2022-07-16       Impact factor: 2.266

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.